Pengbo Guo
Head of Product Development CybernaX Bio
I specialize in lipid nanoparticle (LNP) technologies for nucleic acid delivery, RNA therapeutics, and translational development—spanning from early discovery through GLP-enabling studies to IND filing and strategic commercialization. My expertise lies in engineering next-generation delivery systems, with a focus on novel ionizable lipids, PEG-lipid alternatives, inhalable LNPs, and extrahepatic targeting. At CybernaX Biotechnologies, I lead both product development and business development functions. We are actively seeking strategic partnerships, R&D collaborations, and venture investment to accelerate our growth and impact. CybernaX is a cutting-edge biotechnology company dedicated to advancing delivery platforms for nucleic acid therapeutics. With a robust proprietary lipid library, our innovations support a wide range of applications—including vaccines, oncology, rare diseases, gene editing, early diagnostics, and novel administration routes such as pulmonary delivery. We are committed to enabling transformative RNA-based medicines for patients with unmet needs globally.
Seminars
- Bypassing accelerated blood clearance by reducing recognition from pre-existing and induced anti-PEG antibodies
- Structural design of PEG-alternatives that maintain nanoparticle stability and endosomal escape while minimising immune detection
- Reviewing in vivo and NHP data demonstrating sustained protein expression and low toxicity across longitudinal dosing cycles
